Beyond the Abstract - Second-line therapy for refractory renal-cell carcinoma ... UroToday The pivotal phase III placebo-controlled trial with everolimus (RECORD-1 study), carried out in patients relapsed after first-line treatment with TKIs, proved a statistically significant advantage in terms of PFS in patients treated with the active ... |
